Canbi Pharma Tech Limited

Gilead's breakthrough long-acting HIV therapy receives accelerated review in Europe

Feb 25, 2025

     Gilead Sciences announced today that the European Medicines Agency (EMA) has accepted the company's marketing authorization application (MAA) for lenacapavir, which is administered every six months as a pre exposure prophylaxis (PrEP) therapy for HIV infection. The EMA Human Medicines Committee believes that lenacapavir, which is used every six months to prevent HIV infection, has significant implications for public health and treatment innovation, and its marketing application will be evaluated according to an accelerated assessment schedule. It is worth mentioning that last week, the US FDA announced the acceptance of Gilead Sciences' new drug application (NDA) for lenacapavir for PrEP and granted priority review status to this application. The press release states that EMA's decision represents another regulatory milestone for lenacapavir as a PrEP therapy.

 

    The application submitted to EMA is based on positive data from Phase 3 clinical trials PURPOSSE 1 and PURPOSSE 2 conducted by Gilead Sciences. In PURPOSE 1, the data showed that none of the female subjects who received lenacapavir injection once every six months had HIV infection, the risk of infection was reduced by 100%, showing a significant advantage over the background HIV incidence rate. In PURPOSSE 2, 99.9% of subjects in the lenacapavir treatment group were not infected with HIV, and the risk of infection was reduced by 96% compared to the background HIV infection rate.

 

    In two trials, lenacapavir injected every six months showed significant advantages in preventing HIV infection compared to daily oral Truvada, with overall good tolerability and no major or new safety issues.

 

    Lenacapavir is a "first in class" long-acting HIV viral capsid inhibitor that can interfere with the assembly and disassembly of HIV viral capsid proteins, exerting effects at multiple stages of the virus lifecycle. In 2022, lenacapavir was approved by the European Commission (EC) and the US FDA for use in combination with other antiretroviral drugs to treat adult patients with multidrug-resistant HIV infection. For these AIDS patients who cannot respond effectively to existing therapies, lenacapavir provides a new treatment option twice a year.

 

    It has obtained breakthrough therapy certification from the US FDA for pre exposure prevention of HIV virus infection. In both PURPOSSE 1 and PURPOSSE 2 clinical trials, subjects receiving lenacapavir treatment had a compliance rate of over 90% in receiving injections on time.

 

    In 2024, Science magazine named lenacapavir as the annual scientific breakthrough, saying that this "first in class" drug has brought new dawn for long-term treatment and prevention of AIDS. Recently, the well-known technology media "MIT Technology Review" also listed long-acting HIV infection prevention drugs such as lenacapavir as one of the top 10 breakthrough technologies for 2025, believing that it will have a significant impact on our world in the coming decades.

 

<Reprinted from WuXi AppTec>

 

goTop